<p>IDH-mutant astrocytomas are diffuse gliomas that are defined by characteristic mutations in <i>IDH1</i> or <i>IDH2</i> and do not have complete 1p/19q co-deletion. The established grading criteria include histological features of brisk mitotic activity (grade 3) and necrosis and/or microvascular proliferation (grade 4). In addition, homozygous deletion of the <i>CDKN2A/B</i> locus has recently been implemented as a molecular marker for grade 4 IDH-mutant astrocytomas. Here, we describe a subgroup of high-grade <i>IDH</i>-mutant astrocytomas characterised by a primitive neuronal component based on histology and a distinct DNA methylation profile (n = 51, ASTRO PNC). Misinterpretation as carcinoma metastasis was common, since GFAP expression was absent in the primitive neuronal component, whereas TTF-1 expression was detected in 15/19 cases (79%) based on immunohistochemistry. Apart from mutations in <i>IDH1</i>, <i>TP53</i>, and <i>ATRX</i>, we observed enrichment for alterations in <i>RB1</i> (n = 19/51, 37%) and <i>MYCN</i> (n = 14/51, 27%). Homozygous <i>CDKN2A/B</i> deletion (n = 1/51, 2%) and <i>CDK4</i> amplification (n = 3/51, 6%) were relatively rare events. Clinical (n = 31 patients) and survival data (n = 23 patients) indicate a clinical behaviour similar to other CNS WHO grade 4 IDH-mutant astrocytomas, however with an increased risk for leptomeningeal (n = 7) and extra-axial (n = 2) spread. Taken together, ASTRO PNC is defined by a distinct molecular and histological appearance that can mimic metastatic disease and typically follows an aggressive clinical course.</p>

错误:搜索内容不能为空,请输入英文关键词
错误:关键词超出字数限制,请精简
高级检索

IDH-mutant astrocytomas with primitive neuronal component have a distinct methylation profile and a higher risk of leptomeningeal spread

  • Felix Hinz,
  • Dennis Friedel,
  • Andrey Korshunov,
  • Franziska M. Ippen,
  • Henri Bogumil,
  • Rouzbeh Banan,
  • Sebastian Brandner,
  • Martin Hasselblatt,
  • Henning B. Boldt,
  • Vaidas Dirse,
  • Hildegard Dohmen,
  • Eleonora Aronica,
  • Michael Brodhun,
  • Marike L. D. Broekman,
  • David Capper,
  • Asan Cherkezov,
  • Maximilian Y. Deng,
  • Vera van Dis,
  • Jörg Felsberg,
  • Stephan Frank,
  • Pim J. French,
  • Rüdiger Gerlach,
  • Kirsten Göbel,
  • Eric Goold,
  • Jürgen Hench,
  • Sven Kantelhardt,
  • Patricia Kohlhof-Meinecke,
  • Sandro Krieg,
  • Christian Mawrin,
  • Gillian Morrison,
  • Angelika Mühlebner,
  • Koray Ozduman,
  • Stefan M. Pfister,
  • Pietro Luigi Poliani,
  • Marco Prinz,
  • Guido Reifenberger,
  • Markus J. Riemenschneider,
  • Roman Sankowski,
  • Daniel Schrimpf,
  • Martin Sill,
  • Matija Snuderl,
  • Robert M. Verdijk,
  • Mathew R. Voisin,
  • Pieter Wesseling,
  • Wolfgang Wick,
  • David E. Reuss,
  • Andreas von Deimling,
  • Felix Sahm,
  • Sybren L. N. Maas,
  • Abigail K. Suwala

摘要

IDH-mutant astrocytomas are diffuse gliomas that are defined by characteristic mutations in IDH1 or IDH2 and do not have complete 1p/19q co-deletion. The established grading criteria include histological features of brisk mitotic activity (grade 3) and necrosis and/or microvascular proliferation (grade 4). In addition, homozygous deletion of the CDKN2A/B locus has recently been implemented as a molecular marker for grade 4 IDH-mutant astrocytomas. Here, we describe a subgroup of high-grade IDH-mutant astrocytomas characterised by a primitive neuronal component based on histology and a distinct DNA methylation profile (n = 51, ASTRO PNC). Misinterpretation as carcinoma metastasis was common, since GFAP expression was absent in the primitive neuronal component, whereas TTF-1 expression was detected in 15/19 cases (79%) based on immunohistochemistry. Apart from mutations in IDH1, TP53, and ATRX, we observed enrichment for alterations in RB1 (n = 19/51, 37%) and MYCN (n = 14/51, 27%). Homozygous CDKN2A/B deletion (n = 1/51, 2%) and CDK4 amplification (n = 3/51, 6%) were relatively rare events. Clinical (n = 31 patients) and survival data (n = 23 patients) indicate a clinical behaviour similar to other CNS WHO grade 4 IDH-mutant astrocytomas, however with an increased risk for leptomeningeal (n = 7) and extra-axial (n = 2) spread. Taken together, ASTRO PNC is defined by a distinct molecular and histological appearance that can mimic metastatic disease and typically follows an aggressive clinical course.